Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Uptravi“
Suchtreffer
Begriffe & Kennungen
Uptravi
Eintrag öffnenUptravi · 4.1 Therapeutic indications · 1
Eintrag öffnenUptravi · 4.3 Contraindications · 1
Eintrag öffnenUptravi · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Severe coronar
Eintrag öffnenUptravi · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenUptravi · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenUptravi · 4.5 · 6 The pharmacokinetics of selexipag and its active metabolite are not affected by warfarin.
Eintrag öffnenUptravi · 4.5 · 7 Anticoagulants or inhibitors of platelet aggregation Selexipag is an inhibitor of platelet aggregation in vi
Eintrag öffnenUptravi · 4.5 · Concomitant administration of Uptravi with clopidogrel (loading dose of 300 mg or maintenance dose of 75 mg on
Eintrag öffnenUptravi · 4.5 · Effect of other medicinal products on selexipag
Eintrag öffnenUptravi · 4.5 · Effect of selexipag on other medicinal products
Eintrag öffnenUptravi · 4.5 · Hormonal contraceptives Specific drug-drug interaction studies with hormonal contraceptives have not been cond
Eintrag öffnenUptravi · 4.5 · Inducers of CYP2C8 In the presence of 600 mg rifampicin, once a day, an inducer of CYP2C8 (and UGT enzymes), t
Eintrag öffnenUptravi · 4.5 · Inhibitors and inducers of CYP3A4 In the presence of 400 mg/100 mg lopinavir/ritonavir twice daily, a strong C
Eintrag öffnenUptravi · 4.5 · Inhibitors of CYP2C8 In the presence of 600 mg gemfibrozil, twice a day, a strong inhibitor of CYP2C8, exposur
Eintrag öffnenUptravi · 4.5 · Inhibitors of UGT1A3 and UGT2B7 The effect of strong inhibitors of UGT1A3 and UGT2B7 (valproic acid, probeneci
Eintrag öffnenUptravi · 4.5 · Midazolam At steady state after up-titration to 1 600 micrograms selexipag twice a day, no clinically relevant
Eintrag öffnenUptravi · 4.5 · PAH-specific therapies In the phase 3 placebo-controlled trial in patients with PAH, the use of selexipag in c
Eintrag öffnenUptravi · 4.5 · Selexipag and its active metabolite do not inhibit or induce cytochrome P450 enzymes and transport proteins at
Eintrag öffnenUptravi · 4.5 · Selexipag is hydrolysed to its active metabolite by carboxylesterases (see section 5.2). Selexipag and its act
Eintrag öffnen